## Preparation and *in vitro/in vivo* evaluation of a pantoprazole sodium drug-resin liquid delayed release suspension

Xinyi Tang<sup>1,2,4</sup>, Xianghuan Meng<sup>3</sup>, Ke Li<sup>2,4</sup>, Zhannuan Yin<sup>1,2,4</sup>, Haibing He<sup>4,5</sup> and Hongfei Liu<sup>1,2,3,4</sup>\*

<sup>1</sup>College of Pharmacy, Anhui University of Chinese Medicine, Hefei, People's Republic of China,

<sup>2</sup>Yangtze Delta Drug Advanced Research Institute, Nantong, People's Republic of China,

<sup>3</sup>Jiangsu University, Zhenjiang, People's Republic of China,

<sup>4</sup>Jiangsu Haizhihong Biopharmaceutical Co., Ltd, Nantong, People's Republic of China,

<sup>5</sup>Department of Pharmaceutics, Shen yang Pharmaceutical University, Shen yang, People's Republic of China

Abstract: A drug-resin liquid delayed-release suspension of pantoprazole sodium (PAZ-Na) was prepared to improve the effectiveness, convenience, and safety of peptic ulcer treatment in children, the elderly, and patients with dysphagia. Pantoprazole sodium drug-resin complexes (PAZ-Na-DRC) were prepared using the bath method. The fluidized bed coating method is used to coat it and then add excipients to make a dry suspension prepared before use. The parameters of the in vitro release experimental conditions were optimized, and the drug release curve showed delayed release. Rats were given commercial PAZ-Na enteric-coated pellet capsules and the PAZ-Na delayed release suspension via intragastric administration. The results showed that the  $T_{max}$  of the PAZ-Na delayed release suspension was increased from 2h to 4h compared with the PAZ-Na enteric-coated pellet capsules. Similarly, the  $C_{max}$  was reduced from  $6.162\mu g/mL$  to  $3.244\mu g/mL$  with the concentration-time curve is very gentle compared with the commercial drug capsules. After oral administration, the relative bioavailability of PAZ-Na delayed release suspension (AUC<sub>0-24</sub> of 19.578  $\mu g \cdot h \cdot mL^{-1}$ ) compared with the commercial drug (AUC<sub>0-24</sub> of 17.388  $\mu g \cdot h \cdot mL^{-1}$ ) was 112.67%. The findings showed that the PAZ-Na delayed release suspension for oral administration was successfully formulated with highly improved pharmacokinetic indices.

Keywords: Anion exchange resin, pantoprazole sodium, delayed release suspension.